Helpful Links & Resources
The End of Asbestos: EPA’s Historic Ban and Its Implications
Reading Time: 2 mins
Published On: August 16, 2024
Michael McGrady - author
Michael McGrady is a critically acclaimed journalist based in the U.S. state of Colorado. He has an extensive background covering harm reduction and risk minimization topics within the realm of public health. You can find McGrady’s writing in outlets like Filter Magazine, Inside Sources, The South China Morning Post, and several others across the globe.
More to Read
News & Data
FILTER:
Matthew Davis
3 mins read - September 12, 2024
On September 4, Johnson & Johnson boldly announced a $1.1 billion increase to its proposed talc settlement, This would increase the settlement to more than $9 billion paid...
Matthew Davis
3 mins read - September 10, 2024
Johnson & Johnson is planning to pay an additional $1.1 billion in its proposed settlement to clear up tens of thousands of lawsuits alleging the company, and its baby powder...
Amna Anees
5 mins read - August 28, 2024
In a groundbreaking development, the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to Insilico Medicine’s ISM6331, a potential...
Melissa Bill
5 mins read - August 27, 2024
The consumer products behemoth Johnson & Johnson is now submerged under a barrage of lawsuits accusing the company’s talc-based products of being the root cause of their...
Katie Duquette
6 mins read - August 26, 2024
Asbestos lawsuits are critical for individuals diagnosed with mesothelioma, lung cancer, or other asbestos-related ailments. Such diagnoses can lead to major life adjustments, and...
Matthew Davis
4 mins read - August 24, 2024
The complex negotiations surrounding Johnson & Johnson’s $6.5 billion attempt to settle thousands of lawsuits regarding its talc products have hit a stumbling block,...
August 13, 2024
Avon’s Financial Turmoil: Chapter 11 Bankruptcy Amid Talc-Related Cancer Lawsuits
>READ
Browse Categories
Mesowatch's mission serves as an industry watchdog
and advocates for patients and families affected
by asbestos by providing reliable and up-to-date news
stories and information on asbestos and mesothelioma.
CONTACT US
Information provided by Mesowatch aims to provide legal and financial assistance and should not be considered a substitute for medical advice, treatment or diagnosis. Past performance and settlements do not guarantee or indicate the outcome of an individual case. Viewing this information or interacting with this website does not create an attorney-client relationship.